Watson to buy Actavis for $5.6 billion
PARSIPPANY, N.J. — Watson has announced its intention to acquire Actavis, the company said.
Following news reports Tuesday that the U.S.-based generic drug maker would acquire Switzerland-based Actavis, Watson announced Wednesday that it would buy the latter for $5.6 billion. News media had reported that the deal would be worth $5.9 billion, while there had been estimates in March that Watson would pay up to $7.3 billion.
"The acquisition of Actavis will create the third largest global generics company, substantially completing Watson’s expansion as a leading global generics company," Watson president and CEO Paul Bisaro said. "Actavis dramatically enhances our commercial position on a global basis and brings complementary products and capabilities in the United States."
Watson noted that Actavis operates in more than 40 countries and markets more than 1,000 products around the world, with more than 300 projects in its pipeline and 2011 sales of about $2.5 billion.
No comments found
FDA declines to approve Takeda diabetes drug
DEERFIELD, Ill. — The Food and Drug Administration declined to approve a drug made by Takeda Pharmaceutical, the drug maker said.
Takeda announced that the FDA issued a complete response letter for its regulatory applications for the Type 2 diabetes drug alogliptin and a combination pill that includes alogliptin and pioglitazone, the active ingredient in the drug Actos.
A complete response letter means that the FDA has finished reviewing a drug approval application, but questions remain that preclude approval. In this case, the agency requested additional data about the drugs, which Takeda said it would supply from clinical trials.
Takeda drug Actos has been linked to bladder cancer and this is still being investigated by the FDA
Quest Diagnostics: Rx misuse recorded among majority of Americans
MADISON, N.J. — A recent Quest Diagnostics "Health Trends Report" released Wednesday found that more than 3-in-5 patients (63%) misused their prescription drugs.
After analyzing nearly 76,000 laboratory tests for monitoring prescription drug use, Quest Diagnostics said the findings suggested many Americans take prescription medications in ways that put their health at risk, including such behaviors as missing doses to combining medications with other drugs without a clinician’s oversight. The study found high rates of inconsistency with clinician orders among all specific drug classes tested, including opioid pain medications, such as oxycodone (including OxyContin) (44%); central nervous system depressants, including alprazolam (as well as Xanax) (50%); and the stimulant amphetamine (such as Adderrall) (48%). What’s more, high rates of misuse were found in men and women across all ages, income levels and government and commercial health plan coverage.
Specific findings included:
As many as 70% of children ages 10 to 17 years and 73% of adults ages 18 to 24 years were inconsistent with clinician orders. Older patients also were at risk of misuse, with inconsistent results found in 50% of adults ages 65 years or older that were tested;
Men and women were as equally likely to misuse drugs, with inconsistency rates of 63%, although males used illicit drugs more, with 2-in-10 (21%) testing positive for cocaine, marijuana or PCP, compared with 15% of females;
Inconsistency rates were similar for low-income areas (median income of $29,000 or less) and high-income areas (median income of $80,000 or more), although patients at the lowest income level were more likely to test negative for their prescription drug(s) than those at the highest income level (42% compared to 35% inconsistency, respectively). The findings suggest that less affluent Americans may be more likely to limit or forgo using their prescribed medications for financial reasons. Median income was based on 2010 U.S. Census data by ZIP code;
Evidence of misuse was found in 72% of samples of Medicaid beneficiaries, compared with 60% of patients in Medicare and 62% in a private health plan.
"The current study from Quest Diagnostics, involving a large nationally representative sample of patients undergoing urine drug testing, suggests that many patients do not take potentially dangerous prescription medications as prescribed," said Keith Heinzerling, assistant professor with the UCLA department of family medicine and UCLA Center for Behavioral and Addiction Medicine. "The study provides a unique perspective on the problem of prescription drug misuse by comparing what the doctor indicates is the patient’s prescribed medication to what is actually in the patient’s urine test. These results are sobering, and suggest that changes in prescribing medications — and educating patients in appropriate prescription drug use — are urgently needed."
The entire report now is available at QuestDiagnostics.com/HealthTrends.
No comments found